Q-omics provides the consensus-scored CTBP2P7 profile across patient tissues and cancer cell-line models. CTBP2P7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CTBP2P7 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, CTBP2P7 RNA expression shows 15,847 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where CTBP2P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTBP2P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTBP2P7 survival associations across molecular data types. CTBP2P7 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTBP2P7 RNA expression–survival associations across cancer types. High CTBP2P7 expression shows unfavorable associations in KIRC, LIHC and COAD, but favorable associations in HNSC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CTBP2P7 RNA expression.
This table summarizes CTBP2P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CTBP2P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTBP2P7 shows higher tumor expression in LUAD, BLCA, COAD, UCEC, LIHC and CHOL. The LUAD box plot shows higher CTBP2P7 RNA expression in tumor versus normal tissue (log2 FC = +0.153, t-test p < 0.001).
This table shows molecular features associated with CTBP2P7 in patient tissues and cancer cell lines. In patient samples, CTBP2P7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
